Datapoint: Gilead Shores Up Breast Cancer Indication for Trodelvy
The FDA last week granted Gilead Sciences’ Trodelvy full approval for the treatment of triple-negative breast cancer (TNBC) — clearing the drug for use in TNBC patients who have received two or more prior treatments, with at least one treatment administered in a metastatic setting. Previously, the drug was approved for use in patients who had received at least two prior treatments in a metastatic setting. Trodelvy, which Gilead picked up via its $21 billion acquisition of Immunomedics, Inc. last October, currently holds preferred formulary placement for just 3% of all covered lives. It is not covered for 23% of all insured lives.
SOURCE: MMIT Analytics, as of 4/9/21